Simultaneous Overexpression of miR-126 and miR-34a Induces a Superior Antitumor Efficacy in Pancreatic Adenocarcinoma [Retraction]
Feng S-D, Mao Z, Liu Chunying, Nie Y-S, Sun B, Guo M, Su C. Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma. Onco Targets Ther. 2017;10:5591–5604.
The Editor-in-Chief and Publisher of OncoTargets and Therapy wish to retract the published article.
Concerns were raised to the Editor-in-Chief regarding the possibility of some image manipulation in the published article. The alleged manipulation relates to Figure 2A AdCEAp-EGFP Panc-1 and AdCEAp-EGFP BxPC3. It appears the same image had been used in both panels but with the fluorescence intensity altered.
The authors were asked for an explanation but were unable to provide a satisfactory explanation for the duplicated images and could not clearly account for the altered fluorescence intensity.
The Editor-in-Chief raised doubts about the validity of the results and determined that simply replacing the images in question not been adequately justified by the authors.
The authors wish to apologise for the error.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]